Cardiovascular diseases are a major cause of death across the globe. According to the World Health Organization, the number of deaths caused by these diseases is expected to surpass 23 million by 2030. These are largely lifestyle diseases and about 16% of deaths caused in 2012 were attributed to high blood pressure. Various classes of drugs used to treat cardiac disorders include calcium channel blockers, anti-adrenergic agents, anti-arrhythmic agents, diuretic agents, and angiotensin-converting enzyme (ACE) inhibitors. Nephrological and urological disorders are common complications of cardiovascular diseases and diabetes. Diuretic agents are often prescribed drug class for treating cardiovascular diseases as well as nephrological and urological disorders. Diuretics alternatively termed as water pills aid in elimination of water and salts from the body. Diuretics are primarily used to treat edema caused by renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Diuretics stimulate kidneys to eliminate water and salts from the body, which helps reduce swelling.

Benicar HCT (olmesartan and hydrochlorothiazide) by Daiichi Sankyo and Exforge HCT (amlodipine, hydrochlorothiazide, and valsartan) by Novartis have lost their patents in 2016 and 2014, respectively. Diovan HCT (valsartan and hydrochlorothiazide) by Novartis was among the top selling drugs in the cardiovascular segment, which generated total sales of US$ 3,524 Mn in 2013.  Hyzaar by Merck and Micardis by Boehringer Ingelheim Pharmaceuticals, Inc. are other key drugs available in the market. Increase in cardiovascular diseases, rise in the number of hypertensive patients, escalation in renal and kidney disorders, changing life styles of people, unhealthy habits, and increasing life expectancy of people are key drivers propelling the global diuretics drugs market. However, certain side effects associated with diuretic drugs restrict their use. The global diuretic agents market was valued at US$ 724.6 Mn in 2013 and is anticipated to increase during the forecast period.

The global diuretic agents market can be segmented based on type, application, distribution channel, and region. In terms of type, the global diuretic agents market can be classified into osmotic diuretics such as mannitol; carbonic anhydrase inhibitors such as acetazolamide (dichlorphenamide, metazolamide); loop diuretics such as bumetanide,  furosemide, ethacrynic acid, torasemide; thiazides & thiazide-like diuretics such as (chlorothiazide), clopamide, hydrochlorothiazide, chlorthalidone, indapamide; Na+ channel antagonists such as triamterene, amiloride; and aldosterone antagonists such as spironolactone and eplerenone. Based on application, the global diuretic agents market can be segmented into hypertension, edema, hypercalciuria, diabetes insipidus, and others. In terms of distribution channel, the global diuretics agents market can be segmented into hospital pharmacies, clinics, hospitals, retail pharmacies, and online pharmacies.

Geographically, the global diuretics agents market can be segmented into five major regions: North America, Europe, Asia Pacific (APAC), Latin America, and Middle East & Africa. Asia Pacific held a leading share of the market, followed by North America, in 2016. These two regions are expected to retain their market position from 2017 to 2025. Rising prevalence of hypertensive complications and increasing government initiatives that appear to be moving toward shorter period of patent exclusivity for new drug applications are some factors driving the market in these regions. Moreover, large population, increasing disposable income, and growing awareness among patients are a few factors propelling the market in Asia Pacific. Europe and the Middle East & Africa are likely to create significant growth opportunities for the diuretics agents market during the forecast period. This is attributed to growing geriatric population in these regions.

Key players operating in the global diuretics agents market include Merck & Co., Inc., Boehringer Ingelheim GmbH, Novartis AG, and Teva Pharmaceuticals Industries Ltd.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.


Diuretic Agents Market

Pre Book